Cargando…

KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors

Warthin tumor (WT; synonym: cystadenolymphoma) represents one of the most frequent salivary gland tumors with a frequency equaling or even outnumbering that of pleomorphic adenomas in some series. Histologically, the tumor displays tall columnar oncocytic cells, arranged into two cell-thick layers l...

Descripción completa

Detalles Bibliográficos
Autores principales: Agaimy, Abbas, Mantsopoulos, Konstantinos, Iro, Heinrich, Stoehr, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156774/
https://www.ncbi.nlm.nih.gov/pubmed/36752878
http://dx.doi.org/10.1007/s00428-023-03504-x
_version_ 1785036610052554752
author Agaimy, Abbas
Mantsopoulos, Konstantinos
Iro, Heinrich
Stoehr, Robert
author_facet Agaimy, Abbas
Mantsopoulos, Konstantinos
Iro, Heinrich
Stoehr, Robert
author_sort Agaimy, Abbas
collection PubMed
description Warthin tumor (WT; synonym: cystadenolymphoma) represents one of the most frequent salivary gland tumors with a frequency equaling or even outnumbering that of pleomorphic adenomas in some series. Histologically, the tumor displays tall columnar oncocytic cells, arranged into two cell-thick layers lining variably cystic glands within an organoid lymphoid stroma. Tumors with exuberant squamous metaplasia in response to FNA-induced or other types of tissue injury/infarction have been referred to as “metaplastic WTs.” However, the same terminology was used for tumors with variable mucinous cell and solid or stratified epidermoid proliferations (occasionally mimicking mucoepidermoid carcinoma), although the “metaplasia concept” has never been proven for the latter. We herein investigated 22 WTs showing prominent mucoepidermoid-like or solid oncocytoma-like proliferations without prior FNA or histological evidence of infarction/ trauma using the TruSight Tumor 15 gene panel and KRAS pyrosequencing. As a control, we tested 11 conventional WTs. No statistically significant differences were observed between the two subcohorts regarding patient’s age and tumor size. Six of 22 (27%) proliferating/ metaplastic WTs revealed oncogenic KRAS mutations clustering at codon 12 (exon 2), while all conventional tumors lacked these mutations. Our findings are in line with a neoplastic nature of the epidermoid/ mucoepidermoid proliferations in non-injured “metaplastic” Warthin tumors. We propose the descriptive term “de novo proliferating Warthin tumor” for this variant to distinguish it from infarcted/inflamed genuine metaplastic Warthin tumor.
format Online
Article
Text
id pubmed-10156774
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101567742023-05-05 KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors Agaimy, Abbas Mantsopoulos, Konstantinos Iro, Heinrich Stoehr, Robert Virchows Arch Original Article Warthin tumor (WT; synonym: cystadenolymphoma) represents one of the most frequent salivary gland tumors with a frequency equaling or even outnumbering that of pleomorphic adenomas in some series. Histologically, the tumor displays tall columnar oncocytic cells, arranged into two cell-thick layers lining variably cystic glands within an organoid lymphoid stroma. Tumors with exuberant squamous metaplasia in response to FNA-induced or other types of tissue injury/infarction have been referred to as “metaplastic WTs.” However, the same terminology was used for tumors with variable mucinous cell and solid or stratified epidermoid proliferations (occasionally mimicking mucoepidermoid carcinoma), although the “metaplasia concept” has never been proven for the latter. We herein investigated 22 WTs showing prominent mucoepidermoid-like or solid oncocytoma-like proliferations without prior FNA or histological evidence of infarction/ trauma using the TruSight Tumor 15 gene panel and KRAS pyrosequencing. As a control, we tested 11 conventional WTs. No statistically significant differences were observed between the two subcohorts regarding patient’s age and tumor size. Six of 22 (27%) proliferating/ metaplastic WTs revealed oncogenic KRAS mutations clustering at codon 12 (exon 2), while all conventional tumors lacked these mutations. Our findings are in line with a neoplastic nature of the epidermoid/ mucoepidermoid proliferations in non-injured “metaplastic” Warthin tumors. We propose the descriptive term “de novo proliferating Warthin tumor” for this variant to distinguish it from infarcted/inflamed genuine metaplastic Warthin tumor. Springer Berlin Heidelberg 2023-02-08 2023 /pmc/articles/PMC10156774/ /pubmed/36752878 http://dx.doi.org/10.1007/s00428-023-03504-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Agaimy, Abbas
Mantsopoulos, Konstantinos
Iro, Heinrich
Stoehr, Robert
KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title_full KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title_fullStr KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title_full_unstemmed KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title_short KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
title_sort kras codon 12 mutations characterize a subset of de novo proliferating “metaplastic” warthin tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156774/
https://www.ncbi.nlm.nih.gov/pubmed/36752878
http://dx.doi.org/10.1007/s00428-023-03504-x
work_keys_str_mv AT agaimyabbas krascodon12mutationscharacterizeasubsetofdenovoproliferatingmetaplasticwarthintumors
AT mantsopouloskonstantinos krascodon12mutationscharacterizeasubsetofdenovoproliferatingmetaplasticwarthintumors
AT iroheinrich krascodon12mutationscharacterizeasubsetofdenovoproliferatingmetaplasticwarthintumors
AT stoehrrobert krascodon12mutationscharacterizeasubsetofdenovoproliferatingmetaplasticwarthintumors